In vitro and in vivo evaluation of hydrophilic and hydrophobic polymers-based nicorandil-loaded peroral tablet compared with its once-daily commercial sustained-release tablet

Drug Development and Industrial Pharmacy

Volumn 37, Issue 4, 2011, Pages 436-445

  Tamilvanan, S ^a,b   Venkatesh Babu, R ^b,c   Nappinai, A ^d   Sivaramakrishnan, G ^c  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b ARULMIGU KALASALINGAM COLLEGE OF PHARMACY   (India)

^c SaiMirrah Innopharm (P) Ltd   (India)

^d C L BAID METHA COLLEGE OF PHARMACY   (India)

Author keywords

Ethylcellulose; in vivo bioavailability; nicorandil; peroral tablet

Indexed keywords

AEROSIL; GLIDING AGENT; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; LUBRICATING AGENT; MAGNESIUM STEARATE; MICROCRYSTALLINE CELLULOSE; NICORANDIL; NIKORAN; POLYMER; TALC; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CROSSOVER PROCEDURE; DEGRANULATION; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RABBIT; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TABLET FRIABILITY; TABLET HARDNESS; TABLET THICKNESS; THIN LAYER CHROMATOGRAPHY;

ANIMALS; BIOLOGICAL AVAILABILITY; CELLULOSE; DELAYED-ACTION PREPARATIONS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; METHYLCELLULOSE; NICORANDIL; RABBITS; SILICON DIOXIDE; SOLUBILITY; TABLETS;

EID: 79953235847     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.521161     Document Type: Article

References (25)

1. Udaykumar P, Adhikari P, Periera P. (2003). Safety and efficacy of nicorandil in chronic stable angina - a double blind comparative randomised trial with isosorbide mononitrate. J Indian Acad Clin Med, 4(3):205-09.
2. IONA study group. (2002). Effect of nicorandil on coronary events in patients with stable angina: The impact of nicorandil in angina (IONA) randomized trial. Lancet, 359(9314):1269-75.
3. Reddy KR, Mutalik S, Reddy S. (2003). Once-daily sustained release matrix tablets of nicorandil: Formulation and in vitro evaluation. AAPS PharmSciTech, 4(4):E61.
4. Hogan JE. (1989). Hydroxypropyl methylcellulose sustained release technology. Drug Dev Ind Pharm, 15(27):975-99. (Pubitemid 19199639)
5. Cooper J, Gunn C. (1986). Powder flow and compaction. In: Carter SJ, ed. Tutorial pharmacy. New Delhi, India: CBS Publishers and Distributors, 211-33.
6. Shah D, Shah Y, Rampradhan M. (1997). Development and evaluation of controlled release diltiazem hydrochloride microparticles using cross-linked poly(vinyl alcohol). Drug Dev Ind Pharm, 23(6):567-74. (Pubitemid 27238955)
7. Aulton ME, Wells TI. (1988). Pharmaceutics: The science of dosage form design. London, England: Churchill Livingstone.
8. Martin A. (2001). Micromeritics. In: Martin A, ed. Physical pharmacy. Baltimore, Maryland: Lippincott Williams & Wilkins, 423-54.
9. United States Pharmacopoeia XXII. (2000). Rockville, Maryland: US Pharmacopoeial Convention Inc.
10. Indian Pharmacopoeia. (1996). Ministry of health and family welfare, Government of India, Controller of Publications.
11. Adelbary GA, Tadros MI. (2008). Design and in vitro/in vivo evaluation of novel nicorandil extended release matrix tablets based on hydrophilic interpolymer complexes and a hydrophobic waxy polymer. Europ J Pharm Biopharm, 69:1019-28.
12. Lund W. (1994). The pharmaceutical codex. London, UK: Pharmaceutical Press.
13. British Pharmaceutical Codex. (1976). London, UK: Pharmaceutical Press.
14. Ojha A, Pargal A. (1999). Determination of nicorandil concentrations in human plasma using liquid chromatography. J Pharm Biol Anal, 21:175-78. (Pubitemid 29430153)
15. Rawlins EA. (1977). Bentley's text book of pharmaceutics. London, England: Cassell and Collier MacMillan.
16. Andersson KE. (1992). Clinical pharmacology of potassium channel openers. Pharmacol Toxicol, 70:244-54.
17. Frampton N. (1992). Review of nicorandil and pharmacology and therapeutic efficacy in angina. Drugs, 44:625-55.
18. Kibbe HA. (2000). Hand book of pharmaceutical excipients. London, England: American Pharmaceutical Association, Pharmaceutical Press.
19. Banker GS, Anderson LR. (1987). Tablets. In: Lachman L, Liberman HA, Kanig JL, eds. The theory and practice of industrial pharmacy. Mumbai, India: Varghese Publishing House, 293-345.
20. Food and Drug Administration, Centre for Drug Evaluation and Research. (1997). Guidance for industry on extended release oral dosage forms: Development, evaluation and application of in vitro/in vivo correlations. Rockville, Maryland: FDA.
21. Moore JW, Flanner HH. (1996). Mathematical comparison of dissolution profiles. Pharm Technol, 20(6):64-74. (Pubitemid 126450495)
22. Shargel L, Yu ABC. (1999). Applied biopharmaceutics and pharmacokinetics. 4th edn. Stamford, CT: Appleton and Lange.
23. Rahman N, Siddiqui MR, Azmi SN. (2007). Quantitation of nicorandil in pharmaceutical formulations by spectrophotometry using N-(1-naphthyl) ethylenediamine dihydrochloride as coupling agent. Yakugaku Zasshi, 127(2):367-74. (Pubitemid 46203280)
24. Kinoshita M, Sakai K. (1990). Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drug Ther, 4:1075-88. (Pubitemid 20330472)
25. Kinoshita M, Nishikawa S, Sawamura M. (1986). Comparative efficacy of high-dose versus low-dose nicorandil therapy for chronic stable angina pectoris. Am J Cardiol, 58:733-38. (Pubitemid 17004235)